Therapeutic expression

Most cellular genes are composed of intron and exon sequences. During maturation of the RNA transcript, the introns are excised and the exons are ligated together. This processing step also facilitates export of RNA from the nucleus into the cytoplasm for protein translation. At least one intron and one exon are almost always included in the therapeutic expression cassette to ensure that the engineered transcript is processed in the same manner as the natural cellular transcript. 

Figure 6. An A-linked glycan structure found on honeybee venom protein [64]. The GalNAc residue attached on A-linked oligosaccharides is not found in animal systems. The corresponding transferase gene may need to be deleted to avoid this potentially immunogenic residue on recombinant therapeutics expressed in insect cell hosts.

FK-506 (37) interferes with IL-2 synthesis and release and has a cyclosporin-like profile, but is considerably more potent in vitro. IC q values are approximately 100-fold lower. This neutral macroHde suppresses the mixed lymphocyte reaction T-ceU proliferation generation of cytotoxic T-ceUs production of T-ceU derived soluble mediators, such as IL-2, IL-3, and y-IFN and IL-2 receptor expression (83). StmcturaHy, FK-506 is similar to sirolimus. Mycophenolate mofetil (33), brequinar (34), and deoxyspergualin are in various phases of clinical evaluation. Identification of therapeutic efficacy and safety are important factors in the deterrnination of their utiUty as immunosuppressive agents. 

Another application shows the preparative purification and polishing of a therapeutic fusion protein with a humanized recombinant IgG protein. The fusion protein was expressed by the fermentation of baby hamster kidney cells. The filtered culture supernatant (155 liters) contained 2.2 g of IgG and 75.5 g of total protein. After the immunoglobulins were isolated by expanded bed adsorption and rebuffering, the IgG fraction was bound to Fractogel EMD SOj (M). This column achieved baseline separation of complete antibodies (fusion protein) from small amounts of antibodies lacking the fusion part. The resulting highly purified IgG fraction (110 ml) was diluted to 150 ml and... 

The successful clinical application of RTK-based therapeutics in the last 8 years instigates further research to generate the next generation drugs. Thus, antisense RNAs or dominant-negative receptor mutants are being tested for their ability to reduce receptor expression. 

In conclusion, the discovery of incretins has now come to an end in terms of therapeutic strategy of metabolic diseases since new medicines will be put on the market these coming years. However, a lot more needs to be done with regard to the physiological role of the hormones. Whereas the major filed of investigation for GLP-1 now relates to the effect of the peptide on the central nervous system and on (3-cell proliferation, for GIP it remains to understand its role in the numerous tissues where the corresponding receptor is expressed. 

MMPs for therapeutic interventions is complicated by the fact that MMPs are indispensable for normal development and physiology and by their multifunctionality, possible functional redundancy or contradiction, and context-dependent expression and activity. This complexity was revealed by previous efforts to inhibit MMP activity in the treatment of cancer patients that yielded unsatisfactory results. Doxycycline, at subantimicrobial doses, inhibits MMP activity, and has been used in various experimental systems for this purpose. It is used clinically for the treatment of... 

---